Intellia Therapeutics Financials - Benzinga

Intellia Therapeutics Inc

NTLANASDAQ

Trade with Public

Trade with Public

$12.87

-0.24-1.83%

At close: Aug 28, 5:00 PM EST

$12.87

0.00320.02%

After Hours: Aug 28, 7:58 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Intellia Therapeutics Financials

Intellia Therapeutics (NTLA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.79) by 1.27 percent. This is a 18.37 percent increase over losses of $(0.98) per

Benzinga Newsdesk

PRO
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimates

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of $(1.10) per share

Benzinga Newsdesk

PRO
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of $(1.10) per share

Benzinga Newsdesk

PRO
Intellia Therapeutics Q4 EPS $(0.83) Beats $(0.96) Estimate, Sales $23.017M Beat $12.812M Estimate

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.96) by 13.72 percent. This is a 34.65 percent increase over losses of $(1.27) per share

Benzinga Newsdesk

Earnings Scheduled For February 26, 2026

Benzinga Insights

Earnings Preview For Intellia Therapeutics

Benzinga Insights